Lenalidomide Eg

Lenalidomide, the active ingredient in Lenalidomide Eg, is an immunomodulatory agent presented as a tablet for oral use. Approved in the European Union, it is indicated for the treatment of multiple myeloma, myelodysplastic syndromes with del(5q), and mantle cell lymphoma in adult patients.

GNH USA supplies Lenalidomide Eg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, adhering to EU quality standards and providing reliable global distribution. The company maintains stringent temperature‑controlled storage and shipment practices to preserve product integrity.

Lenalidomide is used in oncology to target malignant plasma cells and related hematologic malignancies.

Multiple Myeloma: improves progression‑free survival and overall response when combined with standard regimens. Myelodysplastic Syndromes with del(5q): reduces transfusion dependence and can achieve cytogenetic remission. Mantle Cell Lymphoma: employed in relapsed or refractory disease to obtain disease control.

Lenalidomide may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Fatigue or weakness - Diarrhea or constipation - Nausea and vomiting - Rash or pruritus - Low blood counts (neutropenia, anemia, thrombocytopenia)

Serious or Rare Side Effects: - Deep vein thrombosis or pulmonary embolism - Severe neutropenia leading to infection - Secondary primary malignancies - Hepatotoxicity - Severe skin reactions such as Stevens‑Johnson syndrome

Before initiating therapy, clinicians should evaluate patient risk factors and monitor for specific safety concerns.

Pregnancy: contraindicated (Category X); teratogenic risk requires effective contraception. Thrombosis risk: assess for clotting history; consider prophylactic anticoagulation. Hematologic monitoring: perform regular CBC to detect neutropenia, anemia, or thrombocytopenia. Renal impairment: evaluate kidney function; dose adjustment may be necessary. Store at ambient temperature: keep below 25 °C, protect from moisture and light in the original container.

Lenalidomide can interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole) – may increase exposure. - Anticoagulants (e.g., warfarin) – heightened bleeding risk. - Live vaccines – risk of uncontrolled infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin) – may reduce drug levels. - Other myelosuppressive agents – additive bone‑marrow toxicity. - NSAIDs – potential for increased renal toxicity, especially in compromised patients.